Bibliographic Details
| Title: |
Caplacizumab improves clinical outcomes and is well tolerated across clinically relevant subgroups of patients with immune-mediated thrombotic thrombocytopenic purpura |
| Authors: |
Pavenski, Katerina, Scully, Marie, Coppo, Paul, Cataland, Spero, Knöbl, Paul, Peyvandi, Flora, Kremer Hovinga, Johanna A., de la Rubia, Javier, Khan, Umer, Marques, Ana Paula, Gunawardena, Sriya |
| Source: |
In Research and Practice in Thrombosis and Haemostasis July 2024 8(5) |
| Database: |
ScienceDirect |
